Clinical trial
Esomeprazole for Treatment of GERD in Pediatric Patients
NCT00228527 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00228527 |
|---|---|
| Title | Esomeprazole for Treatment of GERD in Pediatric Patients |
| Official title | A Phase III, Multicentre, Randomized, Double-blind Parallel-group Study to Evaluate the Safety and Clinical Outcome of Once Daily Esomeprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Pediatric Patients 1 to 11 Years of Age, Inclusive. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, Non-erosive Esophagitis |
| Intervention type | Drug |
| Interventions | Esomeprazole (Nexium) |
| Enrollment | 100 |
| Start date | Oct 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Sep 29, 2005 |
| Last update posted | Nov 19, 2010 |
| Countries | Belgium, France, Italy, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: